Neuroinflammation PET Imaging in CBS/PSP

Pathway Diagram

flowchart TD
    N0["NEUROINFLAMMATION"]
    N1["NEURODEGENERATION"]
    N0 -->|"activates"| N1
    N2["TREM2"]
    N2 -->|"activates"| N0
    N3["OVERVIEW"]
    N3 -->|"therapeutic target"| N0
    N4["TNF"]
    N4 -->|"inhibits"| N0
    N5["NRF2"]
    N5 -->|"activates"| N0
    N4 -->|"activates"| N0
    N6["GFAP"]
    N6 -->|"biomarker for"| N0
    N7["TLR4"]
    N7 -->|"activates"| N0
    N8["BDNF"]
    N8 -->|"activates"| N0
    N9["NLRP3"]
    N9 -->|"activates"| N0
    N6 -->|"activates"| N0
    N10["APOE"]
    N10 -->|"regulates"| N0

Overview

Neuroinflammation imaging using PET tracers provides critical in vivo insights into the inflammatory processes underlying corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Both conditions are characterized by prominent microglial activation and neuroinflammation, which correlate with disease severity, progression, and therapeutic response. This page covers TSPO PET imaging, second-generation tracers, monoamine oxidase B (MAO-B) imaging, magnetic resonance spectroscopy (MRS) for neuroinflammation, and their applications in CBS/PSP diagnosis and treatment monitoring^{1TSPO PET imaging in atypical parkinsonian syndromes: distinct subcortical inflammation patterns2023 · Acta Neuropathologica · DOI 10.1007/s00401-023-02580-7Open reference2Second-generation TSPO PET tracers in atypical parkinsonism: comparison of regional binding patterns2024 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2024.03.012Open reference}.

TSPO PET Imaging

Background and Rationale

The translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor, is a mitochondrial protein highly expressed in activated microglia and reactive astrocytes. Under normal conditions, TSPO expression is low in the brain, but it increases dramatically during neuroinflammation. TSPO PET imaging allows visualization and quantification of microglial activation in vivo, providing a biomarker for neuroinflammatory processes in neurodegenerative diseases including CBS and PSP^{1TSPO PET imaging in atypical parkinsonian syndromes: distinct subcortical inflammation patterns2023 · Acta Neuropathologica · DOI 10.1007/s00401-023-02580-7Open reference}.

TSPO PET imaging has emerged as a powerful tool to:

• Detect early neuroinflammatory changes before clinical symptoms manifest

• Track disease progression and inflammatory burden

• Monitor response to anti-inflammatory therapies

• Differentiate CBS/PSP from other neurodegenerative conditions

• Correlate inflammation levels with clinical severity

First-Generation TSPO Tracers

PK11195

¹¹C-PK11195 was the first TSPO PET tracer developed and remains a benchmark for neuroinflammation imaging. It demonstrates specific binding to TSPO in regions of active neuroinflammation.

Key characteristics:

• High affinity for TSPO in activated microglia

• Demonstrates increased binding in CBS/PSP motor cortex, basal ganglia, and brainstem

• Correlates with disease severity measured by clinical rating scales

• Limitations: high non-specific binding, moderate signal-to-noise ratio

Findings in CBS/PSP:

• ¹¹C-PK11195 PET shows elevated binding in the motor cortex (2-3x control levels) and basal ganglia in CBS patients^{3In vivo mapping of regional microglial activation in PSP using [11C](R)-PK11195 PET2003 · Movement Disorders · PMID 14517969Open reference}

• PSP patients show increased TSPO binding in the substantia nigra, brainstem, and basal ganglia

• Regional patterns differ from Alzheimer’s disease, with more focal inflammation in CBS

• Binding correlates with clinical severity and disease duration

Second-Generation TSPO Tracers

Second-generation TSPO tracers offer improved pharmacokinetics, reduced non-specific binding, and better signal-to-noise ratios compared to PK11195. However, they exhibit variable affinity depending on TSPO polymorphisms (rs6971 polymorphism), which complicates quantitative analysis.

PBR28

¹¹C-PBR28 (also known as ¹¹C-PBR28 or DPA-714 precursor) is a second-generation TSPO tracer with improved binding characteristics.

Advantages over PK11195:

• Higher brain uptake and better signal-to-noise ratio

• Faster kinetics, enabling shorter scanning protocols

• Higher specific-to-non-specific binding ratio

Clinical findings in CBS/PSP:

• PBR28 demonstrates high binding in motor and premotor cortices of CBS patients

• Sensitive to subtle inflammatory changes in early disease stages

• Useful for monitoring anti-inflammatory treatment effects

DPA-714

¹⁸F-DPA-714 is a fluorine-18 labeled TSPO tracer with favorable properties for clinical use.

Key features:

• Longer half-life (110 min) compared to ¹¹C-labeled tracers

• High affinity for TSPO with moderate sensitivity to polymorphism

• Excellent brain penetration and kinetics

Applications in CBS/PSP:

• DPA-714 PET reveals widespread neuroinflammation in CBS, particularly in affected brain regions

• Shows promise for longitudinal tracking of inflammation

• Useful for therapeutic trials targeting microglial activation

GE-180

¹⁸F-GE-180 is a third-generation TSPO tracer with improved specificity and reduced polymorphism effects.

Advantages:

• Lower affinity for the high-affinity TSPO binding site

• Less affected by TSPO polymorphisms

• High signal-to-noise ratio

Emerging data in CBS/PSP:

• Early studies show promising results in tauopathies

• Potential for standardized quantification across patients

TSPO Binding Patterns in CBS vs PSP

Microglial Activation Imaging Beyond TSPO

P2X7 Receptor Imaging

The P2X7 purinergic receptor is specifically expressed on activated microglia and represents a more specific marker of neuroinflammation than TSPO. Several P2X7 PET tracers are under development.

Rationale:

• P2X7 is specifically upregulated in disease-associated microglia

• May provide better specificity for pathogenic neuroinflammation

• Potential to distinguish beneficial vs harmful microglial activation

Tracer development:

• ¹¹C-KB31 shows promising P2X7 binding in preclinical models

• ¹⁸F-JNJ-54173717 has entered early clinical testing

Colony-Stimulating Factor 1 Receptor (CSF1R) Imaging

CSF1R is involved in microglial proliferation and survival. PET tracers targeting CSF1R may allow visualization of microglial density changes.

Emerging tracers:

• ¹⁸F-PBMC (pyrimidine-4,6-dicarboxamide derivative) shows promise for CSF1R imaging

Monoamine Oxidase B (MAO-B) Imaging

Rationale

MAO-B is predominantly expressed in astrocytes and catalyzes the oxidative deamination of monoamines. In neurodegenerative diseases, MAO-B expression increases in astrocytes surrounding tau pathology, making it a biomarker for astrocyte reactivity and neuroinflammation in CBS/PSP^{411C-L-Deprenyl MAO-B PET in parkinsonian syndromes: astrocyte reactivity and diagnostic utility2021 · European Journal of Nuclear Medicine and Molecular Imaging · DOI 10.1007/s00259-021-05312-8Open reference}.

Tracers for MAO-B Imaging

¹¹C-L-Deprenyl (¹¹C-Deprenyl)

¹¹C-L-deprenyl (also known as ¹¹C-deprenyl) binds irreversibly to MAO-B and provides in vivo measurement of MAO-B density.

Characteristics:

• High affinity for MAO-B in brain

• Irreversible binding allows long scanning windows

• Reflects astrocyte density and reactivity

Findings in CBS/PSP:

• Increased ¹¹C-deprenyl binding in basal ganglia and cortical regions in CBS

• PSP shows elevated MAO-B in brainstem and basal ganglia

• Levels correlate with disease severity and progression

¹¹C-SS-PET

¹¹C-SS-PET is a reversible MAO-B tracer with improved kinetics compared to deprenyl.

Advantages:

• Reversible binding enables dynamic quantification

• Less susceptible to baseline effects

• Better for measuring changes over time

Clinical Applications of MAO-B Imaging

MAO-B PET imaging in CBS/PSP serves several clinical purposes:

1. Diagnostic differentiation: MAO-B patterns help distinguish CBS/PSP from other parkinsonian syndromes

2. Disease staging: Higher MAO-B binding correlates with more advanced disease

3. Prognosis: MAO-B levels predict rate of clinical progression

4. Treatment monitoring: MAO-B inhibitors (rasagiline, selegiline) reduce binding, enabling verification of target engagement

Magnetic Resonance Spectroscopy (MRS) for Neuroinflammation

Overview

Magnetic resonance spectroscopy allows non-invasive measurement of brain metabolites that reflect neuroinflammatory processes. Unlike PET, MRS does not require radiotracers and can be performed on standard MRI scanners^{5Magnetic resonance spectroscopy of neuroinflammation in tauopathies: a 3T study2022 · NMR in Biomedicine · DOI 10.1002/nbm.4731Open reference}.

Key Metabolites

Myo-Inositol

Myo-inositol is primarily located in glial cells (astrocytes and microglia) and serves as a marker of glial cell density and activation.

In CBS/PSP:

• Elevated myo-inositol levels in the frontal cortex and basal ganglia

• Reflects astrocyte reactivity and neuroinflammation

• Increases with disease progression

• Correlates with clinical severity scores

Choline

Choline levels reflect membrane turnover and cellular proliferation, including inflammatory cell infiltration.

Findings:

• Elevated choline in affected brain regions in CBS

• Indicates increased inflammatory cell activity

• May help differentiate CBS from AD

Lactate

Lactate accumulation indicates impaired energy metabolism and anaerobic glycolysis, which can result from neuroinflammation.

Clinical significance:

• Elevated lactate in basal ganglia and cortex in CBS/PSP

• Reflects mitochondrial dysfunction and inflammation

• Correlates with disease severity

MRS Protocol Recommendations

Recommended brain regions for CBS/PSP assessment:

Technical parameters:

• PRESS or MEGA-PRESS sequences

• TE = 30-35 ms for optimal metabolite detection

• Voxel size: 8-16 mm³

• Scan time: 15-20 minutes

Therapeutic Implications

Anti-inflammatory Treatment Monitoring

Neuroinflammation PET imaging enables direct monitoring of anti-inflammatory treatment effects in CBS/PSP.

Key applications:

1. Target verification: Confirm that therapeutic agents reach neuroinflammation sites

2. Dose optimization: Identify optimal doses that reduce neuroinflammation

3. Response prediction: Early inflammation reduction may predict clinical benefit

4. Mechanism of action: Verify that treatments reduce microglial activation

Current Therapeutic Targets

Microglial Modulation

• TREM2 agonists: Ongoing development, PET can monitor microglial changes

• CSF1R inhibitors: Reduce microglial proliferation, measurable by TSPO PET

• Minocycline: Antibiotic with anti-microglial effects, studied in PSP

Astrocyte-Targeted Therapies

• MAO-B inhibitors: Rasagiline, selegiline reduce astrocyte reactivity

• Anti-inflammatory agents: NSAID effects measurable by TSPO PET

Future Directions

Emerging applications:

1. Combination biomarkers: TSPO PET + MRS for comprehensive inflammation assessment

2. Personalized medicine: Select patients based on neuroinflammation levels for specific therapies

3. Trial enrichment: Use baseline inflammation levels to enrich clinical trials

4. Network analysis: Correlate inflammation patterns with functional connectivity changes

Summary

Neuroinflammation PET imaging provides critical biomarkers for understanding, diagnosing, and treating CBS and PSP. Key findings include:

• TSPO PET (PK11195, PBR28, DPA-714, GE-180): Reveals microglial activation patterns that differ between CBS and PSP, with CBS showing more focal inflammation in motor cortex and PSP showing more widespread brainstem involvement

• MAO-B imaging (¹¹C-deprenyl): Provides measure of astrocyte reactivity, useful for disease staging and treatment monitoring

• MRS: Offers complementary information on neuroinflammation through myo-inositol, choline, and lactate measurements

• Therapeutic implications: Enables verification of anti-inflammatory treatment effects and guides personalized treatment selection

These imaging modalities provide a comprehensive toolkit for understanding neuroinflammation in CBS/PSP and developing disease-modifying therapies targeting inflammatory pathways.